Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Group Walters Buys 4,335,000 Shares of Stock

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) major shareholder Group Walters purchased 4,335,000 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The stock was acquired at an average cost of $3.50 per share, for a total transaction of $15,172,500.00. Following the transaction, the insider owned 17,844,973 shares in the company, valued at $62,457,405.50. This represents a 32.09% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL opened at $3.82 on Thursday. The stock has a 50 day moving average price of $4.34 and a two-hundred day moving average price of $3.66. The firm has a market capitalization of $273.78 million, a P/E ratio of -1.96 and a beta of 1.92. Zentalis Pharmaceuticals, Inc. has a 52 week low of $1.21 and a 52 week high of $6.95.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its earnings results on Thursday, August 6th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.10). On average, equities analysts forecast that Zentalis Pharmaceuticals, Inc. will post -2.14 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Wall Street Zen lowered shares of Zentalis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research report on Monday, July 6th. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Zentalis Pharmaceuticals in a report on Friday, May 22nd. Mizuho started coverage on shares of Zentalis Pharmaceuticals in a research report on Friday, July 17th. They issued an “outperform” rating and a $8.00 price objective for the company. Finally, Rodman & Renshaw assumed coverage on shares of Zentalis Pharmaceuticals in a research report on Thursday, July 23rd. They issued a “buy” rating and a $11.00 price objective for the company. Four analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $6.75.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. GSA Capital Partners LLP purchased a new position in shares of Zentalis Pharmaceuticals in the 2nd quarter worth about $1,815,000. Seven Fleet Capital Management LP bought a new position in Zentalis Pharmaceuticals during the first quarter valued at about $257,000. Anfield Capital Management LLC grew its position in Zentalis Pharmaceuticals by 239.9% during the fourth quarter. Anfield Capital Management LLC now owns 242,605 shares of the company’s stock valued at $328,000 after buying an additional 171,228 shares during the period. Dimensional Fund Advisors LP increased its holdings in Zentalis Pharmaceuticals by 182.6% during the first quarter. Dimensional Fund Advisors LP now owns 272,034 shares of the company’s stock worth $634,000 after buying an additional 175,771 shares during the last quarter. Finally, 5AM Venture Management LLC increased its holdings in Zentalis Pharmaceuticals by 705.7% during the fourth quarter. 5AM Venture Management LLC now owns 3,947,913 shares of the company’s stock worth $5,330,000 after buying an additional 3,457,913 shares during the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.